Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates

Coherus Oncology

05/08/2026 21:50

Overview
U.S. oncology therapeutics firm's Q2 revenue up 40% yr/yr, slight miss vs analyst expectations
Adjusted net loss for Q2 was wider than analyst consensus
Company cites strong LOQTORZI demand, normalized discontinuation rates, and improved therapy duration

Outlook
Company expects initial data readouts from multiple clinical trials in 2H 2026
Company projects public disclosure of mature data sets in October 2026
A new Phase 1b study in prostate cancer expected to begin in fall 2026

Result Drivers
LOQTORZI VOLUME GROWTH - Co said Q2 revenue increase was primarily driven by higher LOQTORZI sales volumes
STRONG DEMAND AND PATIENT STARTS - Co cited strong demand, highest number of new patient starts since launch, normalized discontinuation rates, and improved therapy duration as supporting growth

Company press release: ID:nGNX1b0SDw

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Slight Miss*
$14.31 mln
$14.40 mln (6 Analysts)
Q2 Adjusted Net Loss
Miss
$30.14 mln
$25.40 mln (4 Analysts)
Q2 Net Loss
 
$20.63 mln
 
Q2 Operating Income
 
-$32.33 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Coherus Oncology Inc is $6.50, about 339.2% above its August 4 closing price of $1.48

Reuters Recommended Reads
Aug 4 - Merck posts better-than-expected second-quarter results on Keytruda strength
Aug 4 - Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Aug 5 - Black Diamond Therapeutics Q2 net loss narrows year over year

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)